Visar resultat 1 - 5 av 8 avhandlingar innehållade ordet sPLA2.
Sammanfattning : Atherosclerosis is a multi-factorial disease and its pathogenesis is still unclear. However, accumulating evidence during recent years has led to the concept that subendothelial retention of atherogenic lipoproteins is the initiating event in atherogenesis. LÄS MER
Sammanfattning : Atherosclerosis is the most common cause of death in the industrialized world. The diseaseis characterized by lipid accumulation and inflammation in the arterial wall, which may leadto obstruction of the blood flow. LÄS MER
3. Mechanisms involved in the regulation of secretory phospholipase A2 Type IIA expression in human arterial smooth muscle cells. Potential role in atherogenesis
Sammanfattning : Experimental and clinical evidence indicates that secretory phospholipase A2 group IIA (sPLA2-IIA) contributes to atherogenesis. Activity of sPLA2-IIA may be pro-atherogenic both in the circulation leading to altered lipoprotein profile and/or locally in the artery wall where it contributes to lipid accumulation both intra and extra cellularly. LÄS MER
4. Proteoglycans, group IIA phospholipase A2, and lipoproteins.Potential involvement in atherogenesis
Sammanfattning : Atherosclerosis is a multifactorial complex disease characterized by a focal accumulation of ApoB-100 containing lipoproteins, extracellular matrix (ECM), and cells in the arterial intima accompanied by an inflammatory reaction. In vivo and in vitro data supports the hypothesis that sulfated extracellular proteoglycans may be responsible for the selective retention of low density lipoproteins (LDL) in the arterial wall. LÄS MER
Sammanfattning : Type 2 diabetes (T2D) and the metabolic syndrome (MetS), two conditions that are rapidly increasing in prevalence, as well as the dyslipoproteinemia and subclinical inflammation characteristic for these conditions, are associated with an increased risk for developing and dying of cardiovascular disease (CVD). The aim of this thesis was to investigate possible atherogenic properties of very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) in T2D and MetS. LÄS MER